| 6.49 0.01 (0.15%) | 02-16 15:37 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.58 | 1-year : | 8.85 |
| Resists | First : | 6.48 | Second : | 7.58 |
| Pivot price | 6.47  |
|||
| Supports | First : | 6.42 |
Second : | 6.38 |
| MAs | MA(5) : | 6.48 | MA(20) : | 6.46 |
| MA(100) : | 5.86 |
MA(250) : | 4.95  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 90 | D(3) : | 90 |
| RSI | RSI(14): 60.2 | |||
| 52-week | High : | 8.69 | Low : | 2.1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FRLN ] has closed below upper band by 39.3%. Bollinger Bands are 93.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 54 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.5 - 6.53 | 6.53 - 6.55 |
| Low: | 6.39 - 6.43 | 6.43 - 6.47 |
| Close: | 6.42 - 6.49 | 6.49 - 6.54 |
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Sat, 27 Jan 2024
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX - GlobeNewswire
Fri, 26 Jan 2024
FREELINE THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn ... - PR Newswire
Thu, 11 Jan 2024
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC - Yahoo Finance
Thu, 23 Nov 2023
Freeline (FRLN) Shares Rise on Merger Agreement With Syncona - Yahoo Finance
Wed, 22 Nov 2023
Why Is Gene Therapy Player Freeline Therapeutics (FRLN) Stock Gaining Today? - Benzinga
Tue, 11 Apr 2023
Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.68e+007 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 48 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.484e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -240 % |
| Return on Assets (ttm) | 960 % |
| Return on Equity (ttm) | -55.5 % |
| Qtrly Rev. Growth | 622000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -153.43 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -11.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.62 |
| Dividend | 0 |
| Forward Dividend | 23930 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|